Efficient Cancer Therapy with a Nanobody-Based Conjugate

Cancer Research

Volumn 64, Issue 8, 2004, Pages 2853-2857

  Cortez Retamozo, Virna ^a   Backmann, Natalija ^a   Senter, Peter D ^b   Wernery, Ullrich ^c   De Baetselier, Patrick ^a   Muyldermans, Serge ^a   Revets, Hilde ^a  

^a DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^b SEATTLE GENETICS INC   (United States)

^c CENTRAL VETERINARY RESEARCH LABORATORY   (United Arab Emirates)

Author keywords

[No Author keywords available]

Indexed keywords

7 (4 CARBOXYBUTANAMIDO)CEPHALOSPORIN MUSTARD; ANTIBODY; BETA LACTAMASE; CARCINOEMBRYONIC ANTIGEN; CEPHALOSPORIN DERIVATIVE; CHLORMETHINE DERIVATIVE; DRUG VEHICLE; MONOMER; NANOBODY; NANOPARTICLE; PHENYLENEDIAMINE DERIVATIVE; PHENYLENEDIAMINE MUSTARD; PRODRUG; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN BINDING; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; BINDING SITE; CANCER; CANCER THERAPY; CONTROLLED STUDY; DRUG ACTIVATION; DRUG CONJUGATION; DRUG DISTRIBUTION; DRUG MANUFACTURE; DRUG RELEASE; DRUG SOLUBILITY; ENTEROBACTER CLOACAE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR STABILITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR REGRESSION; TUMOR XENOGRAFT;

ADENOCARCINOMA; ANIMALS; ANTIBODIES; BETA-LACTAMASES; CARCINOEMBRYONIC ANTIGEN; COLONIC NEOPLASMS; FEMALE; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOCONJUGATES; MICE; MICE, NUDE; NANOTECHNOLOGY; PEPTIDE LIBRARY; TISSUE DISTRIBUTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 10644228142     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-03-3935     Document Type: Article

References (34)

1. Hammarstrom S. The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues. Semin Cancer Biol 1999; 9:67-81.
2. Carter P. Improving the efficacy of antibody-based cancer therapies. Nat Rev Cancer 2001;1:118-29.
3. Willuda J, Honegger A, Waibel R, et al. High thermal stability is essential for tumor targeting of antibody fragments: engineering of a humanized anti-epithelial glycoprotein-2 (epithelial cell adhesion molecule) single-chain Fv fragment. Cancer Res 1999;59:5758-67.
4. Whitlow M, Bell BA, Feng SL, et al. An improved linker for single-chain Fv with reduced aggregation and enhanced proteolytic stability. Protein Eng 1993;6:989-95.
5. Greenberg AS, Avila D, Hughes M, Hughes A, McKinney EC, Flajnik MF. A new antigen receptor gene family that undergoes rearrangement and extensive somatic diversification in sharks. Nature (Lond) 1995;374:168-73.
6. Nuttall SD, Krishnan UV, Hattarki M, De Gori R, Irving RA, Hudson PJ. Isolation of the new antigen receptor from wobbegong sharks, and use as a scaffold for the display of protein loop libraries. Mol Immunol 2001;38:313-26.
7. Hamers-Casterman C, Atarhouch T, Muyldermans S, et al. Naturally occurring antibodies devoid of light chains. Nature (Lond) 1993;363:446-8.
8. Arbabi Ghahroudi M, Desmyter A, Wyns L, Hamers R, Muyldermans S. Selection and identification of single domain antibody fragments from camel heavy-chain antibodies. FEBS Lett 1997;414:521-6.
9. Dumoulin M, Conrath K, Van Meirhaeghe A, et al. Single-domain antibody fragments with high conformational stability. Protein Sci 2002;11:500-15.
10. Vu KB, Ghahroudi MA, Wyns L, Muyldermans S. Comparison of llama VH sequences from conventional and heavy chain antibodies. Mol Immunol 1997;34: 1121-31.
11. Cortez-Retamozo V, Lauwereys M, Hassanzadeh GG, et al. Efficient tumor targeting by single-domain antibody fragments of camels. Int J Cancer 2002;98:456-62.
12. Bagshawe KD. Antibody directed enzymes revive anti-cancer prodrugs concept. Br J Cancer, 1987;56:531-2.
13. Conrath KE, Lauwereys M, Galleni M, et al. β-Lactamase inhibitors derived from single-domain antibody fragments elicited in the Camelidae. Antimicrob Agents Chemother 2001;45:2807-12.
14. Skerra A, Pluckthun A. Assembly of a functional immunoglobulin Fv fragment in Escherichia coli. Science (Wash DC) 1988;240:1038-41.
15. Lindberg F, Normark S. Common mechanism of ampC β-lactamase induction in enterobacteria: regulation of the cloned Enterobacter cloacae P99 β-lactamase gene. J Bacteriol 1987;169:758-63.
16. Nguyen VK, Desmyter A, Muyldermans S. Functional heavy-chain antibodies in Camelidae. Adv Immunol 2001;79:261-96.
17. Els Conrath K, Lauwereys M, Wyns L, Muyldermans S. Camel single-domain antibodies as modular building units in bispecific and bivalent antibody constructs. J Biol Chem 2001;276:7346-50.
18. De Meester F, Joris B, Reckinger G, Bellefroid-Bourguignon C, Frere JM, Waley SG. Automated analysis of enzyme inactivation phenomena. Application to β-lactamases and DD-peptidases. Biochem Pharmacol 1987;36:2393-403.
19. Svensson HP, Kadow JF, Vrudhula VM, Wallace PM, Senter PD. Monoclonal antibody-beta-lactamase conjugates for the activation of a cephalosporin mustard prodrug. Bioconj Chem 1992;3:176-81.
20. Senter PD, Springer CJ. Selective activation of anticancer prodrugs by monoclonal antibody-enzyme conjugates. Adv Drug Deliv Rev 2001;53:247-64.
21. Galleni M, Lindberg F, Normark S, et al. Sequence and comparative analysis of three Enterobacter cloacae ampC β-lactamase genes and their products. Biochem J 1988; 250:753-60.
22. Nuttall SD, Irving RA, Hudson PJ. Immunoglobulin VH domains and beyond: design and selection of single-domain binding and targeting reagents. Curr Pharm Biotechnol 2000;1:253-63.
23. Nygren PA, Uhlen M. Scaffolds for engineering novel binding sites in proteins. Curr Opin Struct Biol 1997;7:463-9.
24. Tanha J, Xu P, Chen Z, et al. Optimal design features of camelized human single-domain antibody libraries. J Biol Chem 2001;276:24774-80.
25. Desmyter A, Transue TR, Ghahroudi MA, et al. Crystal structure of a camel single-domain VH antibody fragment in complex with lysozyme. Nat Struct Biol 1996;3:803-11.
26. Spinelli S, Frenken L, Bourgeois D, et al. The crystal structure of a llama heavy chain variable domain. Nat Struct Biol 1996;3:752-7.
27. Muyldermans S, Lauwereys M. Unique single-domain antigen binding fragments derived from naturally occurring camel heavy-chain antibodies. J Mol Recognit 1999;12:131-40.
28. Chester KA, Begent RH, Robson L, et al. Phage libraries for generation of clinically useful antibodies. Lancet 1994;343:455-6.
29. Osbourn JK, Field A, Wilton J, et al. Generation of a panel of related human scFv antibodies with high affinities for human CEA. Immunotechnology 1996;2:181-96.
30. Kim JC, Roh SA, Koo KH, et al. Enhancement of colorectal tumor targeting using a novel biparatopic monoclonal antibody against carcinoembryonic antigen in experimental radioimmunoguided surgery. Int J Cancer 2002;97:542-7.
31. Davies J, Riechmann L. Single antibody domains as small recognition units: design and in vitro antigen selection of camelized, human VH domains with improved protein stability. Protein Eng 1996;9:531-7.
32. Martsev SP, Chumanevich AA, Vlasov AP, et al. Antiferritin single-chain Fv fragment is a functional protein with properties of a partially structured state: comparison with the completely folded V(L) domain. Biochemistry 2000;39:8047-57.
33. Roux KH, Strelets L, Brekke OH, Sandlie I, Michaelsen TE. Comparisons of the ability of human IgG3 hinge mutants, IgM, IgE, and IgA2, to form small immune complexes: a role for flexibility and geometry. J Immunol 1998;161:4083-90.
34. Napier MP, Sharma SK, Springer CJ, et al. Antibody-directed enzyme prodrug therapy: efficacy and mechanism of action in colorectal carcinoma. Clin Cancer Res 2000;6:765-72.